Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-595-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- potassium diethyl octylphosphonate ethyl octylphosphonate
- EC Number:
- 939-595-5
- IUPAC Name:
- potassium diethyl octylphosphonate ethyl octylphosphonate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Vivo Bio Tech Ltd, Sy # 349/A, Pregnapur-502311, Gajwel, Mandal, Medak District, Telangana
- Age at study initiation: 12 to 13 weeks
- Weight at study initiation:
Mean body weight Body weight range
G1 : 215.166 ± 15.01 191.21 to 244.60g
G2 : 215.756 ± 15.72 191.21 to 241.87g
G3 : 214.956 ± 13.81 189.93 to 239.41g
G4 : 215.421 ± 14.94 184.21 to 238.16g
- Housing:
Rats were housed in standard polysulfone rat cages (size: Length 425 mm x Breadth 266 mm x Height 185 mm) with stainless steel top grill having facilities for pellet food and drinking water in polycarbonate bottle with stainless steel sipper tube.
i. Pre mating / Acclimatization: Two rats of the same sex per cage were housed.
ii. Mating: Female rats were cohabited with males in a 1:1 ratio in same cage.
iii. Post-mating / Treatment: After mating confirmation, females were housed individually.
- Diet (e.g. ad libitum): Teklad Certified (2014C) Global 14 % Protein Rodent Maintenance Diet - Pellet (Certified) manufactured by Harlan Laboratories, P.O.Box 44220, Madison Wi 53744-4220, was provided ad libitum to the animals.
- Water (e.g. ad libitum): Deep bore-well water passed through activated charcoal filter and exposed to UV rays in Aquaguard on-line water filter-cum-purifier manufactured by Eureka Forbes Ltd., Mumbai 400 001, India was provided ad libitum to rats in polycarbonate bottles with stainless steel sipper tubes.
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 23 °C
- Humidity (%): 65 – 68 %,
- Air changes (per hr): 12 to 15
- Photoperiod (hrs dark / hrs light): 12 hours light and 12 hours dark cycle.
IN-LIFE DATES: From: 14 April 2016 To: 13 May 2016
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Dose formulations were prepared once in 3 – 4 days based on the stability results. The prepared dose formulations were divided into daily aliquots and stored in the experimental room (19 to 25 ºC) when not in use.
Required quantities of the test item were weighed in pre-calibrated beakers for each dose level separately and about 3 to 8 mL of vehicle [Milli-Q water] was added and stirred using a glass rod till a uniform solution was obtained and the volume was made up to the mark using the vehicle to get the final desired concentration.
The homogeneity of the Leomin AN Liq formulation during treatment/sampling was maintained by constant stirring using a magnetic stirrer.
Pre-calibration of the beaker to desired volume: Milli-Q water was measured in a graduated cylinder to the final volume of 150 mL. The measured water was transferred into a clean beaker (to be pre-calibrated) and upper and lower meniscus of water was marked on the beaker. Once these lines had been marked, the water was discarded and the beaker was dried. The upper meniscus was used to make up the volume while preparing the dose formulations.
For vehicle control groups, vehicle [Milli-Q water] was administered.
The weight of the test item, the volume of preparation and volume of administration varied depending on the requirement. The unused dose formulations were sent for disposal. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- by Liquid Chromatograph with Mass Spectrometer (LC-MS/MS)
- Details on mating procedure:
- During the mating period, female rats were cohabited with males in a 1:1 ratio. When sperm was detected in a vaginal smear or vaginal plug was observed in the morning, the animal was considered to be mated. This day was considered as day 0 of gestation.
The mated female rats obtained each day were assigned to the treatment groups and vehicle control groups by body weight stratification. This procedure was continued till the required numbers of Day 0 mated females were obtained (24 per group). - Duration of treatment / exposure:
- The dose formulations of test substance was administered orally by gavage using disposable plastic syringe attached with a metal feeding/intubation cannula to rats of low dose (G2), mid dose (G3) and high dose (G4) groups once daily from GD 5 to GD19 of presumed gestation, at approximately the same time each day (varying by± 2 hours).
The dose volume ( at 10 mL/kg) to be administered was calculated based on the body weight of individual animals on first day of treatment
(on GD 5) and was adjusted according to the most recently recorded body weights recorded till GD 19. The animals in the vehicle control group (G1) were handled in an identical manner to the treatment group and were administered vehicle only. - Frequency of treatment:
- Gestation days: 5 to 19
- Duration of test:
- 14 April 2016 to 27 October 2016
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 450 mg/kg bw/day (actual dose received)
- Remarks:
- due to mortality at 800 mg/kg bw/d at high dose of 800 mg/kg bw/d the dosing was reduced to 450 mg/kg bw/d
- Dose / conc.:
- 800 mg/kg bw/day (actual dose received)
- Remarks:
- reduced to 450 mg/kg bw/d on gestation day
- 10: rats no. Rs3891 to Rs3898 (8 rats)
- 9: rats no. Rs3899 to Rs3903 (5 rats)
- 8: rats no Rs3904 to Rs3913 (10 rats)
- 7: rat no. Rs3914
- No. of animals per sex per dose:
- 24 day '0' pregnant rats per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
As per the Sponsor’s suggestion based on the results of a combined repeated dose oral toxicity study with reproduction/developmental toxicity screening test the following doses are selected for definitive embryo-fetal developmental toxicity study with Leomin AN Liq in Wistar rats by oral route:
• G1 - Vehicle control - 0 mg/kg/day
• G2 - Low dose - 50 mg/kg/day
• G3 - Mid dose - 200 mg/kg/day
• G4 - High dose - 800/450 mg/kg/day
- Rationale for animal assignment (if not random): The mated female rats obtained each day were assigned to the treatment groups and vehicle control groups by body weight stratification. This procedure was continued till the required numbers of Day 0 mated females were obtained (24 per group).
Examinations
- Maternal examinations:
- Observations for clinical signs were performed twice a day - pre dose and post dose (within 1-2 hours of administration) during treatment days and once on non-treatment days.
Each rat was observed twice daily for morbidity and mortality i.e., once in the morning and once in the afternoon. Based on the assessment, as there were toxic signs of concern, the observation was carried out twice during weekends and public holidays. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - External examinations: Yes: [all per litter ]
- Soft tissue examinations: Yes: [half per litter ]
- Skeletal examinations: Yes: [ half per litter ]
- Head examinations: Yes: [half per litter ] - Statistics:
- The data on maternal body weight, body weight change, gravid uterine weight, corrected body weight gain, maternal food consumption, number of corpora lutea , number of implantations, total number of fetuses, male and female fetus number and weight was analyzed using ANOVA model, after testing for homogeneity for intra group variance using Levene’s test.
Incidence of pre-implantation loss, post implantation loss, Number of early, late and total resorptions were analyzed using Kruskal Wallis test.
Overall percentage of minor external, visceral and skeletal malformations, Sex ratio and number of dams with any resorptions were analyzed using
2 X 2 Contingency Table.
Statistically significant differences (p < 0.05), indicated by the aforementioned tests were designated by symbol ‘*’ throughout the report. - Indices:
- Maternal Parameters:
- Mean no. of corpora lutea/group = total no. of corpora lutea/total no. of pregnant animals
- Mean no. of implantations/group = total no. of implantations/total no. of pregnant animals
- embryonic resorption index (%) = no. of early resorptions/no. of implantations x 100
- Fetal resorption index (%) = no. of late resorptions/no. of implantations x 100
- Pre-implantation loss/group (%) = no. of CL - no. of implantations/ no. of CL x 100
- Post-implantation loss/group (%) = no. of (early + late) resorptions/total no. of implantations x 100
- Implantation index (%) = no. of implantation sites/ no. of corpora lutea x 100
Litter Paramenters:
- Mean litter size/group = total no. of fetuses/total no. of pregnant animals
- Percentage of abnormal fetuses = no. of abnormal fetuses/total no. of fetuses x 100
- Percentage of live fetuses/group (live fetus index) = no. of live fetuses/total no. of fetuses x 100
- Percentage of dead fetuses/group (dead fetus index) = no. of dead fetuses/total no. of fetuses x 100
- Sex ratio (F:M) = no. of females/no. of males
Other:
- Corrected body weight (carcass weight) = terminal body weight (body weight on GD 20) - unopened uterine weight
- Correctred body weight gain = Corrected body weight - body weight on GD 5
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- In high dose (800/450 mg/kg/day) group, there was treatment related clinical sign of hypoactivity during post dose observation in few rats (8/23) during GD 7- 9 and one rat Rs 3891 was found dead on GD 9 (when treated at 800 mg/kg/day). After the dose was reduced to 450 mg/kg/day, there were no clinical signs and all the rats were normal.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- One animal at 800 mg/kg bw/d.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At 200 mg/kg/day, there was a significant reduction in mean body weights on GD 20 (-6%) as compared to vehicle control group. At 800/450 mg/kg/day, there was a significant decrease in mean body weight on GD 8 (-9%), GD 11 (-11%), GD 14 (-9%), GD 17 (-8%) and GD 20 (-9 %) as compared to vehicle control group.
At 200 mg/kg/day, there was a significant reduction in maternal body weight gain during treatment period GD 5 to 20 (-23 %), and for entire period of gestation GD 0- 20 (-21%), as compared to vehicle control group.
At 800/450 mg/kg/day, there was a significant reduction in maternal weight gain during GD 5 - 8 (-314%), during treatment period GD 5-20 (-37 %), and for entire period of gestation GD 0-20 (-31 %), as compared to vehicle control group.
There was significant reduction in corrected body weight (-7 to -8 %) and weight gain (-111 % to -140 %) at 200 mg/kg/day and 800/450 mg/kg/day respectively as compared to vehicle control group. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- At 200 mg/kg/day, there was a significant reduction in maternal food consumption during GD 11-14 (-23%), GD 14-17 (-13%), during treatment period GD 5-20 (-12%) and for entire gestation period GD 0-20 (-10 %) as compared to vehicle control group.
At 800/450 mg/kg/day, there was a significant reduction in maternal food consumption during GD 5-8 (-48 %), GD 8-11 (-24 %), GD11-14 (-17 %), and during treatment period GD5-20 (-19 %) and for entire gestation period GD 0-20 (-15 %) as compared to vehicle control group. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- There were gross pathological findings of thickening of stomach- non glandular mucosa - multifocal in 8/24 rats at 200 mg/kg/day and 17/23 at 800/450mg/kg/day. The rat found dead had scanty ingesta in stomach and intestine.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related changes observed in litter parameters at all the doses tested. At 50 mg/kg/day there was a significant increase in fetal weight of total live fetuses and female fetuses and a significant decrease in number of female fetuses as compared to vehicle control group these findings were considered incidental and not attributed to treatment.
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed - Changes in number of pregnant:
- no effects observed
- Other effects:
- not specified
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
MATERNAL BODY WEIGHT AND WEIGHT GAIN
The maternal group mean body weights were unaffected by the administration of test item Leomin AN Liq at the dose of 50 mg/kg/day.
At 200 mg/kg/day, there was a significant reduction in mean body weights on GD 20 (-6%) as compared to vehicle control group. At
800/450 mg/kg/day, there was a significant decrease in mean body weight on GD 8 (-9%), GD 11 (-11%), GD 14 (-9%), GD 17 (-8%) and GD 20
(-9 %) as compared to vehicle control group.
At 200 mg/kg/day, there was a significant reduction in maternal body weight gain during treatment period GD 5 to 20 (-23 %), and for entire period of gestation GD 0- 20 (-21%), as compared to vehicle control group.
At 800/450 mg/kg/day, there was a significant reduction in maternal weight gain during GD 5 - 8 (-314%), during treatment period GD 5-20
(-37 %), and for entire period of gestation GD 0-20 (-31 %), as compared to vehicle control group.
There was significant reduction in corrected body weight (-7 to -8 %) and weight gain (-111 % to -140 %) at 200 mg/kg/day and 800/450 mg/kg/day respectively as compared to vehicle control group.
FOOD CONSUMPTION
At 50 mg/kg/day, the maternal food consumption was comparable to vehicle control group.
At 200 mg/kg/day, there was a significant reduction in maternal food consumption during GD 11-14 (-23%), GD 14-17 (-13%), during treatment period GD 5-20 (-12%) and for entire gestation period GD 0-20 (-10 %) as compared to vehicle control group.
At 800/450 mg/kg/day, there was a significant reduction in maternal food consumption during GD 5-8 (-48 %), GD 8-11 (-24 %), GD11-14 (-17 %), and during treatment period GD5-20 (-19 %) and for entire gestation period GD 0-20 (-15 %) as compared to vehicle control group.
The significant reduction in maternal body weights along with concomitant reduction in food consumption at 200 and 800/450 mg/kg/day was considered as treatment-related finding.
Effect levels (maternal animals)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 50 mg/kg bw/day
- Based on:
- other: treatment-related significant reduction in maternal body weight, corrected body weight gain and food consumption
- Basis for effect level:
- other: maternal toxicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 800 mg/kg bw/day
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Fetal body weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- At 50 mg/kg/day there was a significant increase in fetal weight of total live fetuses and female fetuses and a significant decrease in number of female fetuses as compared to vehicle control group these findings were considered incidental and not attributed to treatment.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not examined - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- There was an incidence of small fetus at 200 and 800/450mg/kg/day.
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- No treatment-related changes were observed during skeletal examination of fetuses of dams treated up to 800/450 mg/kg/day.
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- No treatment-related changes were observed during visceral examination of fetuses of dams treated up to 800/450 mg/kg/day.
- Other effects:
- not specified
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
MATERNAL DATA
No treatment-related changes were observed in maternal parameters at 50, and 200 mg/kg/day. There was significant decrease in mean gravid uterine weight (-15%) and non- significant increase in late resorptions, pre and post implantation loss at 800/450 mg/kg/day as compared to vehicle control group. No treatment-related changes were observed in other maternal parameters (mean numbers of corpora lutea, early resorptions, and dams with any resorption).
LITTER DATA
There were no treatment-related changes observed in litter parameters at all the doses tested. At 50 mg/kg/day there was a significant increase in fetal weight of total live fetuses and female fetuses and a significant decrease in number of female fetuses as compared to vehicle control group these findings were considered incidental and not attributed to treatment.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 800 mg/kg bw/day
- Basis for effect level:
- other: teratogenicity
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Based on the above findings, it is concluded that, No Observed Adverse Effect Level (NOAEL) for
Maternal toxicity is 50 mg/kg/day due to treatment-related significant reduction in maternal body weight, corrected body weight gain and food consumption at 200 and 800/450 mg/kg/day and significant reduction in uterine weight at 800/450 mg/kg/day.
Fetal developmental toxicity is 800/450 mg/kg/day in Wistar rats as the litter data parameters were comparable to vehicle control group up to the high dose of 800/450mg/kg/day.
Teratogenicity is 800/450 mg/kg/day as there were no signs of teratogenicity in any of the tested dose levels up to the high dose of
800/450 mg/kg/day
in Wistar rats when Leomin AN Liq was administered orally by gavage during GD 5 to 19 under the test conditions and doses employed in this study. - Executive summary:
The objective of this study was to evaluate theembryo-fetal developmentaltoxicity of test item Leomin AN Liq when administered to pregnant Wistar rats by oral route during gestation days (GD) 5 to GD19.The results of this study helped to establish the No Observed Adverse Effect Level (NOAEL) of the test item.
In this study, each group (G1, G2, G3 and G4) consisted of 24 presumed pregnant Wistar rats (gestation day 0). Day `0' of gestation for each individual female rat in the study was considered as the day on which vaginal smear was found positive for sperm.
The test item, Leomin AN Liq was dissolved in vehicle [Milli-Q water] and administered orally (by gavage) to presumed pregnant rats once daily from GD 5 to 19 at the dose levels of 50, 200 and 800/450 mg/kg/day for low (G2), mid (G3) and high(G4) dose group rats, respectively. The rats in the vehicle control (G1) group received the vehicle alone. A constant dose volume of 10 mL/kg body weight was administered to all groups.
High dose group (G4) rats were treated at the dose of 800 mg/kg/day initially (From 25 April 2016 to 29 April 2016). The rats exhibited treatment related clinical sign of hypoactivity, one rat was found dead on GD 9 and there was drastic reduction in body weight and food intake. Considering the treatment related findings and in consultation with the sponsor, the high dose was reduced from 800 to 450 mg/kg/day
(30 April to 12 May 2016). The dose for the high dose group is presented as 800/450mg/kg/day.The dose formulation solutions were analyzed for active ingredient concentrations at the initiation and termination of treatment. The results of analysis of formulations revealed that the analyzed concentrations were within the acceptable limits.
The mated females were observed twice daily for clinical signs, mortality and morbidity. Body weights were recorded on GD0, 3, 5, 8, 11, 14, 17 and 20. About 200 g (food input) was provided on Day ‘0’. The food left over was recorded and replenished to a known weight on GD 3, 5, 8, 11, 14 and 17. The food left over was also recorded on Day 20 of presumed gestation. The intermittent body weight gain and food intake was calculated and presented for rats found pregnant at caesarean section.
Caesarean section was performed for all the surviving rats on GD 20 and dams were examined for gross pathological changes. The uterus from all the animal were removed (by laparotomy) and the contents were examined.The uteri were weighed and examined for the number of implantation sites, early and late resorptions, and number of live and dead fetuses. The number of corpora lutea was counted on each ovary. All the fetuses were sexed, weighed and examined for external malformations.Approximately half the number of fetuses from each dam was examined for visceral malformations and the remaining half was evaluated for skeletal malformations.
Results of the study are presented below:
· There was no mortality and clinical signs in the low dose and mid dose groups. In the high dose group there was a treatment-related clinical sign of hypoactivity and in addition, one rat (Rs3891) was found dead on GD 9 (when treated at the dose of 800 mg/kg/day). After the dose was reduced to 450 mg/kg/day, there were no clinical signs and all the rats were normal.
· There was treatment-related significant reduction in maternal body weights, corrected body weight gain and food consumption in mid and high dose groups as compared to vehicle control group.
· Gross necropsy finding of thickening of stomach non-glandular mucosa multifocal was observed in 8/24 and 17/23 rats of mid and high dose groups respectively.
· Maternal data parameter - uterine weight was significantly reduced in high dose group. The other maternal data parameters were comparable to vehicle control group up to the high dose.
· Litter data parameters were comparable to vehicle control group at all the doses tested.
· Fetal, external, visceral and skeletal observations were comparable to vehicle control group at all the doses tested. Visceral and skeletal examinations revealed no signs ofteratogenicity in any of the tested doses.
Based on the above findings, it is concluded that, No Observed Adverse Effect Level (NOAEL) for
· Maternal toxicity is 50 mg/kg/day due to treatment-related significant reduction in maternal body weight, corrected body weight gain and food consumption at 200 and 800/450 mg/kg/day and significant reduction in uterine weight at 800/450 mg/kg/day.
· Fetal developmental toxicity is 800/450 mg/kg/day in Wistar rats as the litter data parameters were comparable to vehicle control group up to the high dose of 800/450 mg/kg/day.
· Teratogenicity is 800/450 mg/kg/day as there were no signs of teratogenicity in any of the tested dose levels up to the high dose of 800/450 mg/kg/day
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.